EyePoint (EYPT) Deferred Taxes (2011 - 2025)
EyePoint (EYPT) posted Deferred Taxes of $369000.0 for Q4 2025, up 310.0% sequentially from $90000.0 in Q4 2024, and up 310.0% YoY from $90000.0 in Q4 2024.
EyePoint (EYPT) Deferred Taxes (2011 - 2025) Analysis & Trends
EyePoint has reported Deferred Taxes for 3 years, with the latest figure at $369000.0 in Q4 2025.
- Quarterly Deferred Taxes rose 310.0% year-over-year to $369000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $459000.0 (up 410.0% YoY) and the FY2025 annual result came in at $279000.0, up 210.0% from the prior year.
- Deferred Taxes grew to $369000.0 in Q4 2025 per EYPT's latest filing, from $90000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $369000.0 in Q4 2025 and troughed at $90000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2011 | -13,000.00 |
| Jun 30, 2011 | -119,000.00 |